Logo image of BNTC

BENITEC BIOPHARMA INC (BNTC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BNTC - US08205P2092 - Common Stock

11.76 USD
-0.37 (-3.05%)
Last: 1/15/2026, 9:40:59 AM
Fundamental Rating

3

Taking everything into account, BNTC scores 3 out of 10 in our fundamental rating. BNTC was compared to 528 industry peers in the Biotechnology industry. While BNTC has a great health rating, there are worries on its profitability. BNTC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year BNTC has reported negative net income.
  • In the past year BNTC has reported a negative cash flow from operations.
  • BNTC had negative earnings in each of the past 5 years.
  • In the past 5 years BNTC always reported negative operating cash flow.
BNTC Yearly Net Income VS EBIT VS OCF VS FCFBNTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10M -20M -30M -40M

1.2 Ratios

  • With a Return On Assets value of -39.75%, BNTC perfoms like the industry average, outperforming 59.47% of the companies in the same industry.
  • With a decent Return On Equity value of -42.86%, BNTC is doing good in the industry, outperforming 70.08% of the companies in the same industry.
Industry RankSector Rank
ROA -39.75%
ROE -42.86%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BNTC Yearly ROA, ROE, ROICBNTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BNTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BNTC Yearly Profit, Operating, Gross MarginsBNTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5K -10K -15K -20K -25K

More info and screens

8

2. Health

2.1 Basic Checks

  • There is no outstanding debt for BNTC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BNTC Yearly Shares OutstandingBNTC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
BNTC Yearly Total Debt VS Total AssetsBNTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • An Altman-Z score of 29.11 indicates that BNTC is not in any danger for bankruptcy at the moment.
  • BNTC's Altman-Z score of 29.11 is amongst the best of the industry. BNTC outperforms 92.99% of its industry peers.
  • BNTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 29.11
ROIC/WACCN/A
WACCN/A
BNTC Yearly LT Debt VS Equity VS FCFBNTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 14.80 indicates that BNTC has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 14.80, BNTC belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
  • BNTC has a Quick Ratio of 14.80. This indicates that BNTC is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 14.80, BNTC belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.8
Quick Ratio 14.8
BNTC Yearly Current Assets VS Current LiabilitesBNTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 80.10% over the past year.
EPS 1Y (TTM)80.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 10.96% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.58%
EPS Next 2Y9.85%
EPS Next 3Y10.96%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BNTC Yearly Revenue VS EstimatesBNTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2027 2028 5M 10M 15M 20M 25M
BNTC Yearly EPS VS EstimatesBNTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • BNTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNTC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNTC Price Earnings VS Forward Price EarningsBNTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNTC Per share dataBNTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.85%
EPS Next 3Y10.96%

More info and screens

0

5. Dividend

5.1 Amount

  • BNTC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BENITEC BIOPHARMA INC

NASDAQ:BNTC (1/15/2026, 9:40:59 AM)

11.76

-0.37 (-3.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)02-12
Inst Owners81.88%
Inst Owner Change0.04%
Ins Owners0.53%
Ins Owner Change0%
Market Cap398.19M
Revenue(TTM)N/A
Net Income(TTM)-41.82M
Analysts87.69
Price Target25.7 (118.54%)
Short Float %4.81%
Short Ratio6.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.27%
Min EPS beat(2)-41.99%
Max EPS beat(2)41.44%
EPS beat(4)3
Avg EPS beat(4)22.44%
Min EPS beat(4)-41.99%
Max EPS beat(4)57.97%
EPS beat(8)4
Avg EPS beat(8)-91.3%
EPS beat(12)6
Avg EPS beat(12)-100.3%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.08%
PT rev (3m)-3.69%
EPS NQ rev (1m)13.85%
EPS NQ rev (3m)40.27%
EPS NY rev (1m)12.61%
EPS NY rev (3m)41.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.08
P/tB 4.08
EV/EBITDA N/A
EPS(TTM)-1.21
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS0
BVpS2.88
TBVpS2.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -39.75%
ROE -42.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.8
Quick Ratio 14.8
Altman-Z 29.11
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.17%
EPS Next Y31.58%
EPS Next 2Y9.85%
EPS Next 3Y10.96%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-104.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.12%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.59%
OCF growth 3YN/A
OCF growth 5YN/A

BENITEC BIOPHARMA INC / BNTC FAQ

What is the fundamental rating for BNTC stock?

ChartMill assigns a fundamental rating of 3 / 10 to BNTC.


What is the valuation status of BENITEC BIOPHARMA INC (BNTC) stock?

ChartMill assigns a valuation rating of 0 / 10 to BENITEC BIOPHARMA INC (BNTC). This can be considered as Overvalued.


How profitable is BENITEC BIOPHARMA INC (BNTC) stock?

BENITEC BIOPHARMA INC (BNTC) has a profitability rating of 1 / 10.


What is the earnings growth outlook for BENITEC BIOPHARMA INC?

The Earnings per Share (EPS) of BENITEC BIOPHARMA INC (BNTC) is expected to grow by 31.58% in the next year.